Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lil...( INDIANAPOLIS Dec. 14 /- Eli Lilly...)

INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Robert Conley, M.D., will join Lilly in January, 2008, as a Distinguished Lilly Scholar focusing on schizophrenia and other psychotic illnesses.

"We are absolutely delighted to have Dr. Conley join our team here at Lilly," said Jack Harris, M.D., vice president, U.S. Medical Division. "Rob is a well-known thought leader, clinician and scientist who brings important experience to Lilly as we continue to realize our vision of serving the patient. His experience will allow him to play a key scientific leadership role in our relationships with the U.S. physician community as well as the broader clinical and scientific communities."

Conley joins Lilly from the University of Maryland in Baltimore, where he is professor of psychiatry and pharmacy science. His work there focused on developing better treatments for patients with schizophrenia and other psychotic illnesses. With his colleagues at the Maryland Psychiatric Research Center and the National Institute on Drug Abuse, he also helped improve treatment for patients with poorly responsive schizophrenia through increased understanding of the most effective and safest ways to use antipsychotics.

After receiving his bachelor's degree from the John Hopkins University, Conley earned his medical degree from the University of Maryland in Baltimore. He did post-graduate work at the Western Psychiatric Institute & Clinic at the University of Pittsburgh before joining the faculty at the University of Maryland in Baltimore. He is an accomplished author and serves on numerous national peer-review boards.

"I am very pleased that Rob has decided to join Lilly," said Alan Breier
'/>"/>